Sheldon M. Feldman, MD

home / authors / sheldon-m-feldman-md

Articles

Sheldon Feldman, MD

Dr Feldman on the Prevention and Management of Breast Cancer–Related Lymphedema

Sheldon M. Feldman, MD
August 14th 2024

Sheldon Feldman, MD, discusses prevention and management strategies for breast cancer–related lymphedema.

Read More

Sheldon M. Feldman, MD

Dr Feldman on New Approaches for Decreasing the Risk of Breast Cancer–Related Lymphedema

Sheldon M. Feldman, MD
July 20th 2024

Sheldon Feldman, MD discusses new approaches for decreasing the risk of and managing breast cancer¬–related lymphedema.

Read More

Latest Updated Articles

Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: August 22nd 2024 | Updated: August 29th 2024
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Published: August 6th 2024 | Updated: August 19th 2024
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
OncLive’s August Roundup of Key FDA Approvals in Oncology
Published: September 4th 2024 | Updated: September 8th 2024
OncLive’s August Roundup of Key FDA Approvals in Oncology
Paula Rodriguez-Otero, MD, PhD
Published: June 4th 2024 | Updated: September 8th 2024
D-VRd Boosts MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Multiple Myeloma